感染与免疫中心的科研人员近年来在Nature, Science, Cell, Immunity, Nature Medicine, PNAS, JEM 等国际权威刊物上发表文章一百多篇，其中陈建柱教授和刘勇军教授还获得多项免疫学技术专利。除中科院百人计划以外，几年来许多教授和科研人员在国内和国外还获得了多种奖项，并承担了多项重大课题的攻关任务：
 
   
唐宏： 2001～2004年 基金委“国家杰出青年”基金（A类）资助。
973项目“动脉粥样硬化的信号转导网络及其调控”
973项目非典专项“SARS病毒细胞内吞与融合机制研究”
“十五”863艾滋专项“新型HIV防治疫苗的研制”
863“结构基因组”专项基金子课题
 
   
刘阳： T32 CA90223-01A1 Funding period, Dec 1, 01- Nov 30, 06.
B7 receptors for tumor immunotherapy and immune regulation Type: R01(CA69091, Year 5-9). Period: 5/1/00-6/30/04.
Response and tolerance to an unmutated tumor antigen P1A. Type: R01 (CA58033, Year 6-9). Period: 12/1/97-11/30/07.
Costimulation and significance of negative selection Type R01 12/01/02-11/30/07
Two signal regulation of NK immunity Type P01 CA954201project 3 09/30/02-9/29/07
 
   
陈建柱： ( 专利 )

Jianzhu Chen, Qing Ge, and Herman N. Eisen. The use of short interference RNA to prevent and treat influenza virus infection. US Provisional Application No.: 60/446,377
Qian Huang, Joan F. L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eisen, and Richard A. Young. In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent. US Provisional Application No.: 60/176,143
 
   
刘勇军： ( 专利 )

Molecular cloning of a novel disintegrin-proteinase from human dendritic cells. (DNAX patent USA).
Molecular cloning of human RP105 (DNAX patent USA).
Molecular cloning of a novel serine proteinase inhibitor from hematopoietic stem cells(DNAX patent USA).
Generation of type 1 IFN-producing cells from hematopoietic stem cells (DNAX patent USA)
CpG and poly Ⅰ:C stimulate different subpopulation of dendritic cells to produce type -1 IFN (DNAX patent).
Molecular cloning of a novel terosine kinase antagonist from viral infected pre-DC2 (DNAX patent USA).
Human Toll Like Receptor.
Human IL-50 activated DCs strongly activate T cells to produce IL-13, IL-4 and TNF-alpha.
 
   
苏立山： Active

NIH RO1-AI41356 (Su) 4/1/98-3/31/08 (25%)
HIV-1 Pathogenesis in the Human Thymus.
NIH RO1-AI/GM 48407-01 (Su) 09/01/00-08/31/05 (20%)
A Novel RhoA Effector Involved in Modulating HIV-1 Replication and Pathogenesis.
NIH R01-CA72433 Consortia (PI: Y. Zhuang); (Collaborator: Su) 4/1/2002-3/31/2004 (5%)
Functions of E2A in T cell leukemogenesis.
NIH R21-CA99939-01 (Su). 9/1/02-8/31/04 (15%)
Adaptive evolution of HIV-1 in “genetically humanized” mouse models.
NIH R21 AI53804-01 (Su) 09/30/2002 – 8/31/2004 (20%)
Genetic Analysis of Chemokine Receptors in Human T Cell Development
NIH R21-HL72240-01. 9/1/2002-8/31/2005 (20%)
A novel genetic approach to dissecting homing and engraftment of HSPC
Completed

America for AIDS Research (Amfar). 6/1/01-5/31/02
Paracrine Suppression Factors of HIV Replication in LTNP Patients. The goals of this project are to identify novel anti-HIV host factors that modulate immune responses.
 
   
王盛典： 2003－2004 Principle Investigator, Molecular engineering of B7-H1 and B7-DC molecules to enchance tumor immunity. Fraternal of Eagles Foundation for Cancer Research.